Hospital del Mar

South Korean medical AI company Lunit has recently secured deals with hospitals in Europe, where the medical device market – the second largest after the North American market – is worth $155 billion. It won the contract to supply a lung disease screening solution to TeleDiag, the largest teleradiology group in France. Lunit was also chosen to provide a mammography analysis solution to the central region branch of the Liga Portuguesa Contra o Cancro (Portuguese League Against Cancer), which oversees Portugal's national breast cancer screening programme. The organisation aims to use Lunit's AI to analyse about 100,000 mammograms annually for the next three years. Another Korean company, Coreline Soft, bagged contracts in Europe to supply its AI screening software. Following a competitive bidding process, it will provide the University Hospital Lausanne in Switzerland with its flagship product, AVIEW LCS Plus, which uses AI to identify lung nodules, pulmonary emphysema, and coronary artery calcification in chest X-rays. The same software is also being implemented in the respective lung disease research of two French hospitals, the Bichat–Claude Bernard Hospital under Europe's largest hospital system, Assistance Publique–Hôpitaux de Paris, and the private, not-for-profit Foch Hospital in Suresnes, a commune in western Paris. Hospital del Mar, a general hospital in Barcelona, Spain, is also adopting Coreline's AI screening tool for its clinical research on lung cancer. The hospital is part of the European lung cancer screening project, 4-In-The-Lung-Run, of which Coreline is also a technology partner. Omnichannel pharmacy chain Zeno Health has acquired e-pharmacy startup Tablt Pharmacy for an undisclosed amount, the Times of India reported. The acquisition expands Zeno's network to the rural communities of Eastern India. Tablt is currently serving 200,000 customers in nearly 300 franchises across Bengal, Odisha, Bihar and Jharkhand. In the next five years, Zeno looks to grow its franchises to 1,000, co-founder and CEO Siddharth Gadia said. Kakao Healthcare is collaborating with online startup Brave Company to develop exercise content for blood sugar management. Their respective health and exercise experts will work together to create content, which will be released on Brave's various healthcare platforms and Kakao's latest mobile app, Pasta. Brave also seeks to tap online content creators to promote their upcoming exercise content.

LONDON, March 27, 2024 (GLOBE NEWSWIRE) -- Lightpoint Surgical Limited (Lightpoint), an affiliate of Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a world-first bladder cancer sentinel lymph node (SLN) procedure with SENSEI®, Telix's miniature robotic-assisted gamma probe used to detect radiation in patients and guide surgery. The patient was operated on at Hospital del Mar in Barcelona, Spain. SENSEI® is smaller than an AA battery and designed specifically for robotic-assisted and minimally invasive surgery. The miniature size and proprietary features make the technology ideal for tight surgical spaces such as around the bladder. With broad application in radio-guided surgery across multiple procedures and major cancer types, SENSEI® is currently indicated for use during SLN biopsy in prostate, endometrial and cervical cancers. As part of an investigator-initiated clinical trial, SENSEI® was used by Dr. Lluís Cecchini with the da Vinci Xi surgical robotic platform in a patient scheduled for radical cystectomy and Bricker urinary diversion with SLN biopsy. Dr. Lluís Cecchini, Head of Urology at Hospital del Mar said, "Lymph nodes around the bladder have a high chance of being cancerous and are therefore important to excise. Radio-guided surgery has historically been limited by the fact that gamma probes are generally only suitable for open surgery. The size and flexibility of SENSEI® meant it was easy to manipulate within the surgical cavity, see the gamma signal within the robotic console, and quickly locate the SLN, where I might otherwise not have known it was present. Being able to perform the procedure with minimal impact on surrounding healthy tissue is a high surgical priority. With SENSEI® we can deliver a more targeted, focused, and less complex experience for patients." Nynke van den Berg, General Manager Medical Technologies (MedTech) at Telix added, “A first bladder cancer procedure with the SENSEI® drop-in gamma probe is a significant milestone for Telix and the Lightpoint team. As we focus on aligning SENSEI® with our Illuccix® and TLX599-CDx programs for prostate cancer, this successful procedure demonstrates the potential and scope to expand use into other urologic malignancies – in line with our portfolio approach to support the patient from diagnosis to surgical intervention and therapy.” About SENSEI® Lightpoint has developed SENSEI® - a miniaturised surgical gamma probe for minimally invasive and robot-assisted surgery. The device is approved for sale in the US, EU, UK, and Australia and is in clinical use in the US, UK, Germany, France, Netherlands, Belgium, and Spain. About Lightpoint Lightpoint Surgical Ltd (Lightpoint) is an affiliate of Telix Pharmaceuticals Limited. As the MedTech division of Telix, Lightpoint is focused on the development of precision-guided surgical solutions and complementary Artificial Intelligence technologies to aid detection, management and treatment of cancer and rare diseases. Lightpoint is headquartered in the United Kingdom. Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email: kyahn.williamson@telixpharma.com Legal Notices The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. The information contained in this announcement is subject to change without notification. This announcement may contain forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the ASX or on our website. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions. ©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals, Lightpoint, Illuccix® and SENSEI® names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.

The international research team, led by HKUST life science professor Nancy IP, developed an advanced blood test for the early detection of AD and mild cognitive impairment (MCI), with accuracy rates of more than 96% and 87% respectively The HKUST-led team developed the blood test for AD and MCI. (Credit: PRNewswire/The Hong Kong University of Science and Technology) A research collaboration led by the Hong Kong University of Science and Technology (HKUST) has developed a universal blood test for Alzheimer’s disease (AD) and cognitive impairment. The research team was led by HKUST president and life science professor, and the Hong Kong Centre for Neurodegenerative Diseases (HKCeND) director Nancy IP. They developed an advanced blood test for the early detection of AD and mild cognitive impairment (MCI), with accuracy rates of more than 96% and 87% respectively. The research was conducted in collaboration with researchers at University College London, UK and the Barcelonaβeta Brain Research Centre in Barcelona, Spain. It is also supported by clinicians from local and overseas hospitals including the Prince of Wales Hospital in Hong Kong, and the Hospital del Mar in Barcelona, Spain. Professor IP said: “Our blood test heralds a new era of simple, effective, and less invasive diagnostics, and by expanding the scope of our research to include diverse populations, we have taken a crucial step towards making our test a universally applicable tool for AD diagnosis. “Our test can also be used to screen suitable individuals for specific drug treatments in clinical studies, and closely monitor disease progression and drug responses. “In the future, it may also facilitate the development of personalized treatments, by shedding light on the molecular underpinnings of AD that vary from person to person and between ethnicities.” AD is a brain disorder characterised by the accumulation of toxic amyloid beta (Aβ) in the brain, resulting in progressive memory loss, cognitive decline, and difficulties in daily tasks. The recent approval of Lecanemab, an antibody intravenous (IV) infusion therapy targets MCI or mild AD-related dementia with elevated Aβ in the brain. However, most individuals with AD and MCI are often undiagnosed and untreated, largely due to the challenges in making an early diagnosis. Currently, elevated Aβ can be measured through brain imaging or invasive procedures, which involve observation of symptoms that appear 10 to 20 years after the onset of the disease. The research team led by Nancy IP have developed a blood test for the early detection of AD and MCI with high accuracy. In a study of people of Chinese and European ethnicity, the blood test showed superior performance in distinguishing people with AD and MCI from cognitively normal people, along with detecting brain amyloid pathology. The study findings also showed that the test can be applicable across diverse ethnic and regional boundaries, with the potential to make a global impact. Unlike existing blood assays that primarily focus on a single biomarker analysis to reveal brain pathology, the new blood test simultaneously measures the levels of 21 proteins. The blood test reveals the alterations in multiple crucial biological pathways and delivers accurate classification of AD and MCI, along with close monitoring of disease progression. Also, it provides a comprehensive AD pro everyone, which allows for the future development of personalised treatment approaches for individual patients.